Antiphospholipid syndrome

This study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…

This trial tests whether sirolimus (rapamycin), an immune-suppressing drug, can safely raise platelet counts in people with antiphospholipid antibodies and persistent low platelets. Participants are randomly assigned to receive sirolimus or a placebo for six months, and those who…

This early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…

This study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and…

This study is testing a new blood filter called the Plasma Filter PX2. It is used in a procedure called therapeutic plasma exchange, which removes harmful substances from the blood of people with autoimmune diseases. About 46 adults will take part, and the study will check if the…

This study tests the safety of an experimental drug called anifrolumab in 20 adults with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots and pregnancy complications. Participants receive weekly injections of the drug for up to 52 weeks, alongside …

This study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…

This early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…

This study tests whether daratumumab, a drug used for certain cancers, is safe for people with antiphospholipid syndrome (APS), an autoimmune disorder that raises blood clot risk. Up to 22 adults will receive weekly infusions for 8 weeks at different doses. The main goal is to ch…

This early-stage trial is testing a drug called RAY121 in 144 people with one of six immune diseases, including antiphospholipid syndrome and bullous pemphigoid. The drug works by blocking a specific part of the immune system (the complement pathway) that can cause tissue damage.…

This study tests whether adding certolizumab (Cimzia) to standard care (heparin and aspirin) can prevent fetal death or early delivery in pregnant women with antiphospholipid syndrome (APS) and lupus anticoagulant. About 55 women will receive the drug early in pregnancy and be co…

This early-stage study tests a new mRNA-based treatment (ABO2203) for people with autoimmune diseases that haven't improved with standard care. The therapy works by directing the body's immune cells to attack and control overactive immune cells causing the disease. The study will…

This early-stage study tests a new cell therapy called YTS109 in 18 adults aged 18-65 with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and…

This early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune …

This early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the d…

This study collects information from 150 adults with antiphospholipid syndrome who had an artery clot in the past year. Participants are already on one of four blood-thinning treatments. Researchers will track who has another clot or a major bleed over two years to see which trea…

This study is testing a new blood test called Cryocheck HexLA to see if it can detect lupus anticoagulant (LA) more accurately than current tests. Researchers will compare the new test with standard tests using blood samples from 200 adults. The goal is to find a test that is bot…

This study is testing a new blood test (the HMEC test) to see if it can better identify which patients with thrombotic microangiopathy (TMA) have a specific immune system problem driving their disease. TMA is a severe condition that damages kidneys and the brain. The researchers …

This study is testing whether the shingles vaccine (RZV) works and is safe for adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus who are taking immune-suppressing drugs. Two hundred participants will receive two doses of the vaccine. Researchers will me…

This study is looking for the genes that cause certain immune system problems. Researchers want to understand why some people get sick and others don't, even in the same family. Up to 5,000 people with immune disorders and their relatives will give blood or cheek cell samples for…

This study will analyze DNA from up to 20,000 people, including those with immune disorders and their relatives, to find genetic variants linked to conditions like atopy, autoimmunity, and primary immunodeficiency. Researchers will also study how best to return genetic results to…

This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…

This study is measuring a protein called STIM1 on the surface of immune cells in 670 people with various autoimmune diseases. The goal is to find which diseases have high levels of this protein, which could help researchers develop new antibody-based treatments. Participants prov…

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This study follows up to 5,000 people with autoinflammatory diseases (like NOMID, CANDLE, and juvenile dermatomyositis) and their healthy relatives. Researchers will collect medical history, blood samples, and imaging over 2-5 day visits to learn how these diseases work and find …

This study looks for inherited genes that may increase the risk of developing antiphospholipid antibody syndrome (APS), a condition that causes abnormal blood clotting, leading to problems like strokes, heart attacks, and miscarriages. Researchers will recruit 2,800 people with A…

This study is creating a global registry of 500 adults with antiphospholipid syndrome (APS) who are taking direct oral anticoagulants (DOACs) like rivaroxaban or apixaban. Researchers will track rates of recurrent blood clots and bleeding over at least 6 months. The goal is to ga…

This study looks at whether a doctor's computer tool (MedSafer) and patient brochures (EMPOWER) can help reduce the use of potentially harmful medications in adults aged 60 and older with rheumatic diseases who take five or more regular drugs. Researchers will follow 100 particip…

This observational study is following 700 pregnant women with lupus or antiphospholipid syndrome across nine medical centers. Researchers are looking at specific proteins in the blood to see if they can predict serious pregnancy complications like fetal death, preterm delivery, o…

This study collects and freezes testicular tissue from boys and young men who are at risk of becoming infertile due to cancer, autoimmune disorders, or their treatments. The tissue is stored in a research bank, with the hope that future medical advances will allow it to be used t…

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…

This study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…

This study is building a large registry and biorepository of 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and scleroderma. Researchers at Yale University will collect medical data and biological samples over time to better understand these condit…

This study looks at two types of blood thinners—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—to see which works better at preventing repeat blood clots in people with a low-risk form of antiphospholipid syndrome (APS). APS is an autoimmune condition that ra…

This registry enrolls pregnant women or those planning pregnancy who have autoimmune diseases like lupus or rheumatoid arthritis. Researchers at Duke University will track health data to find ways to improve outcomes for mothers and babies. The goal is to better understand risk f…

This study is creating a registry to collect information from children diagnosed with antiphospholipid syndrome (APS), a condition that causes abnormal blood clots. Researchers aim to better understand what causes APS and how it is treated, with a focus on long-term survival. The…

This study looks at how often antiphospholipid syndrome (APS) occurs in people aged 65 and older who have had a stroke or mini-stroke. Researchers will test blood for specific antibodies linked to APS, including some newer ones not yet standard. The goal is to better understand A…

This study looks at a protein called annexin A2 on the surface of certain white blood cells (monocytes) in people with antiphospholipid syndrome, a condition that raises the risk of blood clots and pregnancy complications. Researchers will compare the amount of this protein betwe…

This study follows 200 adults with antiphospholipid syndrome (APS) to see how often blood clots return and how well current treatments work. Researchers will also look at treatment side effects, risk factors, and death rates. No new treatment is being tested; the goal is to gathe…